What IBS actually is, what drives it, and what the evidence says about managing it
Irritable bowel syndrome is a common, long-term condition that affects the gut. It is characterised by recurrent abdominal pain and changes in bowel habit — diarrhoea, constipation, or alternating between both — without any structural or biochemical abnormality to explain them.
That last part is important. IBS is not caused by damage, inflammation, or a detectable disease process in the gut. Blood tests and scans come back normal. Colonoscopies look normal. This is sometimes misinterpreted to mean that IBS is "all in the head" — it isn't. The condition is real, the symptoms are real, and they are driven by genuinely abnormal gut functioning. It's just that the abnormality lies in how the gut and the brain communicate, not in the gut's physical structure.
IBS is now formally classified as a disorder of gut-brain interaction — previously called a functional bowel disorder. This is the terminology used by the Rome Foundation, which sets the international diagnostic criteria for these conditions.
IBS is divided into subtypes based on the predominant bowel pattern. This matters because management differs between them.
Loose, watery stools; urgency; frequent bowel movements. Often triggered by eating. Most common subtype overall.
Hard, lumpy stools; straining; feeling of incomplete emptying. Bloating particularly prominent. More common in women.
Both loose stools and constipation — often alternating. The most complex subtype to manage. Significant bloating.
Meets IBS criteria but doesn't fit neatly into D, C, or M categories. Stool pattern varies or is inconsistent.
IBS is not a single disease with a single cause. It is better understood as a syndrome — a collection of symptoms arising from several different, overlapping mechanisms:
IBS is a clinical diagnosis — made from the history, not from tests. The Rome IV criteria require recurrent abdominal pain at least one day per week for the past three months, associated with two or more of: change in stool frequency, change in stool form, or pain relieved or worsened by defecation. Crucially, there should be no alarm features to suggest a different diagnosis.
Before diagnosing IBS, a GP will usually do a limited set of tests to exclude conditions that can mimic it. A full blood count checks for anaemia (which can indicate IBD or cancer). CRP looks for systemic inflammation. Coeliac serology (anti-tTG IgA with total IgA) is essential — coeliac disease can look exactly like IBS-D and is missed surprisingly often. Faecal calprotectin is a stool test that distinguishes gut inflammation from functional symptoms with good accuracy.
A colonoscopy is not needed for typical IBS in a younger patient with no alarm features. It may be appropriate in patients over 50 with new symptoms, or where there is diagnostic uncertainty.
| Test | What it checks for |
|---|---|
| Full blood count + CRP | Anaemia, inflammation — raises suspicion of IBD or malignancy |
| Coeliac serology (anti-tTG IgA) | Coeliac disease — very common mimic of IBS-D |
| Faecal calprotectin | Gut inflammation — helps distinguish IBS from IBD |
| Thyroid function | Hypothyroidism (constipation) / hyperthyroidism (diarrhoea) |
| Hydrogen breath test | Lactose intolerance, SIBO — if dietary history suggests these |
Management of IBS is stepped — start with the least intensive, best-evidenced approach and escalate if needed. Most people improve significantly with first and second-line measures.
Regular meals, no skipping, adequate fibre (soluble fibre for IBS-C, reduced insoluble fibre for IBS-D), reduction of alcohol and caffeine, adequate hydration. NICE CG61 recommends physical activity — evidence supports modest but real symptom improvement.
The strongest dietary evidence for IBS. Restrict fermentable carbohydrates for 4–6 weeks, then systematically reintroduce to identify individual triggers. Requires dietitian guidance to do correctly and avoid nutritional deficiency. Effective in approximately 50–70% of people with IBS.
Antispasmodics (mebeverine, hyoscine) for cramps and urgency — taken before meals. Loperamide for IBS-D when dietary measures are insufficient. Laxatives (macrogol/polyethylene glycol) for IBS-C. Peppermint oil capsules — modest evidence for abdominal pain and bloating.
Low-dose amitriptyline (10–30 mg at night) — now firmly evidence-based following the 2023 ATLANTIS trial. Superior to placebo for IBS symptom scores across all subtypes. Your GP can prescribe this. Gut-directed hypnotherapy and CBT — both have strong evidence, comparable to dietary therapy, particularly effective when anxiety is a feature.
A 2020 Lancet Gastroenterology systematic review and meta-analysis by Oka and colleagues pooled data from studies worldwide using consistent Rome criteria. Using Rome III criteria, pooled global prevalence was 9.2%. Using the more restrictive Rome IV criteria, it was 3.8%. Prevalence was higher in women than men, highest in younger adults, and varied substantially by country — from under 1% to over 25%. The authors noted the methodology used to define IBS has a substantial effect on the numbers obtained, which is why prevalence figures in the literature vary so widely.
Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterology & Hepatology 2020;5(10):908–917. DOI: 10.1016/S2468-1253(20)30217-X
Sperber and colleagues conducted the largest global study of functional gastrointestinal disorders, surveying 73,076 adults across 33 countries using Rome IV criteria. More than 40% of the global sample met criteria for at least one functional GI disorder. IBS was among the most prevalent, with pooled global prevalence of approximately 4.1% by Rome IV — more than 1 in 25 adults worldwide. The study confirmed that IBS reduces quality of life and increases healthcare utilisation substantially, and that it is significantly underdiagnosed and undertreated globally.
Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology 2021;160(1):99–114.e3. DOI: 10.1053/j.gastro.2020.04.014
Peters and colleagues at Monash University conducted a randomised trial comparing gut-directed hypnotherapy, low-FODMAP diet, and the combination in 74 IBS patients. At six weeks, all three approaches produced significant and comparable reductions in gastrointestinal symptoms. At six months, the effects were durable and similarly maintained across groups. Hypnotherapy additionally improved psychological indices — anxiety and quality of life measures — more than diet alone. This trial established that gut-directed hypnotherapy is a clinically comparable alternative to dietary intervention for IBS, with additional benefit for psychological wellbeing.
A note on placebo-controlled evidence. This trial compared two active treatments — it had no placebo or no-treatment arm. The vs-placebo evidence for each intervention comes from separate studies. For gut-directed hypnotherapy, the landmark placebo-controlled trial is Whorwell et al. (Lancet 1984), which randomised 30 patients with severe refractory IBS to hypnotherapy or psychotherapy plus placebo — the hypnotherapy group showed dramatic improvement across all symptoms, with no relapses at three-month follow-up. For low-FODMAP, truly blinding a dietary intervention is methodologically very difficult; Gibson (J Gastroenterol Hepatol 2017) reviewed six RCTs comparing low-FODMAP to placebo-type approaches and found uniformly positive results, with approximately 70% of patients responding.
Peters SL, Yao CK, Philpott H, Yelland GW, Muir JG, Gibson PR. Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome. Alimentary Pharmacology & Therapeutics 2016;44(5):447–459. DOI: 10.1111/apt.13706
Whorwell PJ, Prior A, Faragher EB. Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. The Lancet 1984;2(8414):1232–1234. DOI: 10.1016/S0140-6736(84)92793-4
Gibson PR. The evidence base for efficacy of the low FODMAP diet in irritable bowel syndrome: is it ready for prime time as a first-line therapy? Journal of Gastroenterology and Hepatology 2017;32(Suppl 1):32–35. DOI: 10.1111/jgh.13693
The ATLANTIS trial, published in The Lancet in 2023, is the largest trial of a tricyclic antidepressant for IBS ever conducted. Ford and colleagues randomised 463 adults with IBS across 55 GP practices in England to low-dose amitriptyline (10–30 mg nightly) or placebo for six months. Amitriptyline was significantly superior to placebo on the primary outcome — IBS Severity Scoring System score at six months (mean difference −27.0 points, p=0.0079). It was also superior for global symptom relief. The authors concluded that GPs should offer low-dose amitriptyline to patients whose symptoms do not improve with first-line therapies. The number needed to treat (NNT — how many patients need to be treated for one to benefit compared to placebo) was 6 — meaning for every six patients treated, one additional person achieves meaningful relief compared to placebo.
Ford AC, Wright-Hughes A, Alderson SL, et al.; ATLANTIS trialists. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2023;402(10414):1773–1785. DOI: 10.1016/S0140-6736(23)01523-4
The Rome IV criteria, published in Gastroenterology in 2016 by Mearin, Lacy, Chang and colleagues on behalf of the Rome Foundation, are the current internationally agreed diagnostic criteria for IBS and other functional bowel disorders. The paper classifies IBS as a disorder of gut-brain interaction, defines the four subtypes (IBS-D, IBS-C, IBS-M, IBS-U), and sets the diagnostic threshold as recurrent abdominal pain at least one day per week for three months, associated with two or more of: change in stool frequency, change in stool form, or pain related to defecation. The Rome IV criteria replaced Rome III (which required three days per month) and removed the term "discomfort" — pain is now required. These criteria underpin virtually all modern IBS clinical trials and are the standard used by the NHS for diagnosis.
Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel Disorders. Gastroenterology 2016;150(6):1393–1407.e5. DOI: 10.1053/j.gastro.2016.02.031
IBS is one of the conditions most poorly served by the traditional model of medicine — where a scan or blood test tells you what's wrong. With IBS, the investigations are normal. That doesn't mean the patient is fine. It means the problem lies in a system we can't easily image: the gut-brain axis.
The good news is that the evidence base has never been stronger. Dietary therapy, psychological therapy, and medication all have solid trial evidence. The 2023 ATLANTIS trial in particular has given GPs a clear signal that low-dose amitriptyline should be offered more widely as second-line treatment — not reserved for specialist centres.
If you have IBS — you deserve a proper explanation of what it is, a structured management plan, and access to the treatments that work. Don't accept "everything's normal, it's probably stress" without more.
This article is health education, not medical advice. It is intended to help you understand IBS and the evidence around it — not to replace a consultation with your own doctor. If you are concerned about any symptoms, that is a conversation for you to have with your GP or healthcare professional.